Skip to main content
Explore URMC

menu

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Research Question:
Does the drug Obeticholic Acid help treat patients with primay biliary cholangitis?

Basic Study Information

Purpose:
Primary Biliary Cholangitis (PBC) formerly known as primary biliary cirrhosis is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) helps prevent liver damage and improves liver function. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC patients.

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Chelsea Vallone
Phone: (585) 275-4763
Email: chelsea_vallone@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search